Biotechnology

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufact...

2024-10-09 23:37 3245

The CDE has Granted Breakthrough Therapy Designation to LBL-024, a Bispecific Antibody that Targets PD-L1 and 4-1BB, Developed by Leads Biolabs, for the Treatment of Extrapulmonary Neuroendocrine Carcinoma.

NANJING, China, Oct. 9, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation to LBL-024, an anti-PD-L1/4-1BB bispecific antibody indepe...

2024-10-09 13:38 2312

AWAK Transforms into Vivance, Unveiling a New Brand Identity

SINGAPORE, Oct. 9, 2024 /PRNewswire/ -- AWAK Technologies, a pioneer in innovative kidney care is excited to announce its rebranding toVivance. The name, derived from 'viva' and 'advance', embodies vitality and progress - hallmarks of the company's commitment to revolutionizing kidney health. AW...

2024-10-09 08:00 2935

LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance

GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...

2024-10-08 20:30 3822

Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor One of two EGFR programs being developed with Scorpion Therapeutics CASTRES, France and BOSTON, Oct. 8, 2024 /PRNewswire/ -- Pierre Fabre Laboratories, a glo...

2024-10-08 20:00 2125

Registrational Phase III Studies of APG-2449 Cleared by China CDE for the Treatment of Patients with NSCLC

ROCKVILLE, Md. and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that APG-2449, a FAK/ALK...

2024-10-08 10:26 2871

Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...

2024-10-08 08:00 3011

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of68Ga-PSMA-11[1] injection) to select patients for...

2024-10-08 04:00 2525

The U.S. Fish and Wildlife Service Rejects Petition to List Long-Tailed Macaques Under the Endangered Species Act

WASHINGTON, Oct. 8, 2024 /PRNewswire/ -- On October 7, 2024, the U.S. Fish and Wildlife Service ("USFWS" or "the Service") declined to accept a petition filed by People for the Ethical Treatment of Animals (PETA) and other advocacy groups to list long-tailed macaque ("LTM") monkeys (Macaca fascic...

2024-10-08 03:31 2559

GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials

PLANTATION, Florida and HOUSTON, Texas, Oct. 8, 2024 /PRNewswire/ -- GBI Biomanufacturing, a leading Contract Development and Manufacturing Organization (CDMO), andAllterum Therapeutics, a Fannin-Founded Company, are pleased to announce a manufacturing partnership to advance Allterum's lead candi...

2024-10-08 00:00 1702

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...

2024-10-07 13:14 2750

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutic...

2024-10-04 13:03 6579

Agilent and National University of Singapore Launch Center of Excellence in Cell Metabolism to Improve Population Health

Center will enable targeted and untargeted metabolic profiling for population-based large-scale cohorts across translational research SINGAPORE, Oct. 4, 2024 /PRNewswire/ -- Agilent Technologies Inc.

2024-10-04 09:00 3904

First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery

MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentu...

2024-10-04 04:00 3505

A*STAR and Flagship Pioneering Announce Partnership to Spur Biotech Innovation in Singapore

Organizations Plan to Jointly Advance Breakthrough Solutions in Human Health and Sustainability, Drive Research Collaboration, Entrepreneurship and Accelerate Talent Development SINGAPORE, Oct. 3, 2024 /PRNewswire/ -- The Agency for Science, Technology and Research (A*STAR),Singapore's lead publ...

2024-10-03 09:00 2619

Precision Medicine Group Welcomes Margaret Keegan as CEO

-- Founding CEO Mark Clein named Executive Chairman; Mr. Clein and co-founder Ethan Leder to continue as Board Directors -- BETHESDA, Md., Oct. 1, 2024 /PRNewswire/ -- Precision Medicine Group (Precision), a leading next-generation provider of drug development and commercialization services, to...

2024-10-01 20:49 1951

Frost & Sullivan co-published Recombinant Type III Triple-Helix Collagen Whitepaper with Everon Healthcare

SHANGHAI, Oct. 1, 2024 /PRNewswire/ -- Frost & Sullivan and Everon Healthcare have conducted extensive investigation across the recombinant collagen Industry and co-published the "Recombinant Type III Triple-Helix Collagen Whitepaper" on Sep. 29th, 2024, which aims to analyze the latest research a...

2024-10-01 17:28 2457

Great Place To Work® Australia and New Zealand names 15 Best Workplaces in Healthcare, Biopharma & Social Assistance in 2024

SYDNEY, Oct. 1, 2024 /PRNewswire/ -- Great Place To Work® ANZ, the global authority on workplace culture today announces theirinaugural 15 Best Workplaces™ in Healthcare, Social Assistance and BioPharma in 2024.   The companies are announced across two lists: Best Workplaces in Biotechnology a...

2024-10-01 07:00 9048

GenEditBio Secures Strategic Investment from Gobi Partners GBA to Accelerate Breakthrough Genome Editing Technologies

HONG KONG, Sept. 30, 2024 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a biotech company co-founded by Prof. ZHENG Zongli from the CityUniversity of Hong Kong that focuses on precision genome editing to provide affordable "precision DNA surgery" for genetic diseases with unmet needs, is ple...

2024-09-30 19:36 3081

Multiple Study Results of Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) at 2024 CSCO Congress

CHENGDU, China, Sept. 29, 2024 /PRNewswire/ -- From September 25th to 29th, the 27th China Clinical Oncology Congress and the 2024 CSCO Annual Meeting were held inXiamen. Experts and scholars in the field of oncology from all over China gathered together to discuss the hotspots at the forefront o...

2024-09-29 11:52 3288
1 ... 38394041424344 ... 186